Abeona Therapeutics (ABEO) Expected to Announce Quarterly Earnings on Wednesday

Abeona Therapeutics (NASDAQ:ABEO) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Abeona Therapeutics to post earnings of ($0.14) per share and revenue of $14.82 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 8:30 AM ET.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.12). The firm had revenue of $11.38 million during the quarter, compared to analysts’ expectations of $12.24 million. On average, analysts expect Abeona Therapeutics to post ($0.88) EPS for the current fiscal year and ($0.14) EPS for the next fiscal year.

Abeona Therapeutics Stock Up 0.4%

Shares of ABEO stock traded up $0.01 during trading hours on Wednesday, hitting $4.26. 41,097 shares of the company’s stock traded hands, compared to its average volume of 1,249,560. The company has a quick ratio of 6.40, a current ratio of 6.63 and a debt-to-equity ratio of 0.01. The stock’s fifty day simple moving average is $5.17 and its two-hundred day simple moving average is $5.48. Abeona Therapeutics has a 12-month low of $4.00 and a 12-month high of $7.65. The stock has a market cap of $243.87 million, a price-to-earnings ratio of -3.92 and a beta of 1.50.

Wall Street Analyst Weigh In

Several brokerages recently commented on ABEO. Cantor Fitzgerald increased their price objective on shares of Abeona Therapeutics from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, September 18th. Weiss Ratings cut Abeona Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, August 17th. Oppenheimer reaffirmed an “outperform” rating and set a $21.00 price objective (down from $22.00) on shares of Abeona Therapeutics in a report on Friday, August 14th. UBS Group reissued a “buy” rating on shares of Abeona Therapeutics in a research report on Friday, September 25th. Finally, Wall Street Zen upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Insider Activity

In other Abeona Therapeutics news, Director Mark Alvino sold 15,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $5.86, for a total transaction of $87,900.00. Following the transaction, the director owned 62,065 shares of the company’s stock, valued at $363,700.90. This represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Brendan M. O’malley sold 6,727 shares of the company’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $5.16, for a total value of $34,711.32. Following the sale, the senior vice president owned 421,226 shares of the company’s stock, valued at $2,173,526.16. This represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 55,428 shares of company stock worth $296,508 over the last 90 days. 7.10% of the stock is owned by corporate insiders.

About Abeona Therapeutics

Abeona Therapeutics Inc (NASDAQ: ABEO) is a biopharmaceutical company focused on developing and commercializing cell and gene therapies for serious and rare genetic diseases. The company’s programs are designed to address conditions with limited treatment options, including diseases caused by genetic defects affecting the skin and other tissues.

Abeona’s lead product, prademagene zamikeracel, is an autologous cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), a rare inherited disorder that causes fragile skin and chronic wounds.